Literature DB >> 19698968

EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.

Jianqiao Xiao1, Joel M Palefsky, Rossana Herrera, Carl Sunshine, Sharof M Tugizov.   

Abstract

We previously showed that the EBV glycoprotein BMRF-2 contains a functional integrin-binding Arg-Gly-Asp (RGD) domain that plays an important role in viral infection and cell-to-cell spread of progeny virions in oral epithelial cells. In this study, we found that EBV-seropositive human sera contain antibodies against BMRF-2. The inhibitory effect of EBV-positive sera on EBV infection of oral epithelial cells was substantially reduced by pre-incubation of serum samples with the BMRF-2 RGD peptide, suggesting that anti-BMRF-2 human antibodies possess neutralizing activity. EBV-specific sera reacted strongly with the BMRF-2 extracellular domain (170-213 aa) containing the RGD motif, whereas they reacted only weakly or not at all with a mutated form of the BMRF-2 extracellular domain containing AAA instead of RGD. These data indicate that RGD motif of BMRF-2 is part of an immunodominant antigenic determinant within the extracellular domain of BMRF-2 that may contribute to EBV neutralization during EBV reactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19698968      PMCID: PMC2771626          DOI: 10.1016/j.virol.2009.07.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  57 in total

1.  Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

Authors:  A L Chapman; A B Rickinson; W A Thomas; R F Jarrett; J Crocker; S P Lee
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

2.  Epstein-Barr virus BDLF2-BMRF2 complex affects cellular morphology.

Authors:  Jens-Bernhard Loesing; Stefano Di Fiore; Klaus Ritter; Rainer Fischer; Michael Kleines
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

3.  Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease.

Authors:  Karen A McAulay; Tanzina Haque; Gillian Urquhart; Christopher Bellamy; Deisy Guiretti; Dorothy H Crawford
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

4.  The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein.

Authors:  Mindy Gore; Lindsey M Hutt-Fletcher
Journal:  Virology       Date:  2008-11-07       Impact factor: 3.616

5.  EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells.

Authors:  Jianqiao Xiao; Joel M Palefsky; Rossana Herrera; Jennifer Berline; Sharof M Tugizov
Journal:  Virology       Date:  2009-04-24       Impact factor: 3.616

6.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

Authors:  Etienne M Sokal; Karel Hoppenbrouwers; Corinne Vandermeulen; Michel Moutschen; Philippe Léonard; Andre Moreels; Michèle Haumont; Alex Bollen; Françoise Smets; Martine Denis
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

7.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Authors:  Junji Sashihara; Peter D Burbelo; Barbara Savoldo; Theodore C Pierson; Jeffrey I Cohen
Journal:  Virology       Date:  2009-07-07       Impact factor: 3.616

8.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Authors:  Barbara Savoldo; Cliona M Rooney; Antonio Di Stasi; Hinrich Abken; Andreas Hombach; Aaron E Foster; Lan Zhang; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

Review 9.  Avoiding the void: cell-to-cell spread of human viruses.

Authors:  Quentin Sattentau
Journal:  Nat Rev Microbiol       Date:  2008-11       Impact factor: 60.633

10.  A gamma-herpesvirus glycoprotein complex manipulates actin to promote viral spread.

Authors:  Michael B Gill; Rachel Edgar; Janet S May; Philip G Stevenson
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

View more
  3 in total

1.  Epstein-Barr virus transcytosis through polarized oral epithelial cells.

Authors:  Sharof M Tugizov; Rossana Herrera; Joel M Palefsky
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

2.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

3.  Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.

Authors:  Harman Malhi; Leah J Homad; Yu-Hsin Wan; Bibhav Poudel; Brooke Fiala; Andrew J Borst; Jing Yang Wang; Carl Walkey; Jason Price; Abigail Wall; Suruchi Singh; Zoe Moodie; Lauren Carter; Simran Handa; Colin E Correnti; Barry L Stoddard; David Veesler; Marie Pancera; James Olson; Neil P King; Andrew T McGuire
Journal:  Cell Rep Med       Date:  2022-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.